Ellex is committed to helping you better diagnose, manage and treat a wide range of visual problems and eye diseases. Whether you are involved in the treatment and diagnosis of cataract, glaucoma or retinal disease, Ellex has a solution for your practice, and for your patients.
Offering superior energy control, a sharp-edged aiming beam and the fastest firing rate at 3 shots per second, Ellex’s proprietary SLT technology allows you to visualize the TM in greater detail, and to perform procedures faster and with improved accuracy.
YAG laser vitreolysis offers a simple outpatient-based treatment for vitreous opacities and strands. Highly effective, it has a low complication rate and offers a high degree of patient satisfaction. Featuring perfectly coaxial illumination and ultra-low energy optical breakdown, Ultra Q Reflex™ is ideally suited to the treatment of floaters.
The tough demands of today’s new-generation intraocular lenses (IOLs) require an ever-increasing level of accuracy during YAG surgery. For this reason, Ellex YAG lasers feature state-of-the-art technology designed to achieve precise optical breakdown at the lowest energy levels possible.
Ellex solid-state photocoagulators provide safe, predictable and consistent energy delivery through a true, continuous-wave laser beam. Offering superior energy distribution from beginning to end of exposure, and across the full diameter of the treatment spot, each system delivers consistently better performance in the treatment of retinal disease.
Pattern Scanning Photocoagulation
Unlike conventional photocoagulation, pattern scanning photocoagulation uses millisecond pulse durations, which limit the potential for damage to surrounding tissue. The result is targeted burns with minimal collateral damage to surrounding tissue.
Ultrasound is one of the most fundamental diagnostic tools in ophthalmology. Even in an era of high-tech OCT scanning and digital imaging, ultrasound is the only means to obtain a crucial view of the posterior segment when there is a dense cataract or vitreous hemorrhage in the eye.
Achieving the desired therapeutic effect whilst avoiding the coagulative damage that is associated with ALT, SLT is now seen as a viable alternative to medications in patients with newly diagnosed glaucoma.
The pressure damage of glaucoma causes a gradual blurring of vision and, if left untreated, can result in total, irreversible blindness. SLT is a simple, yet highly effective laser procedure that reduces the intraocular pressure associated with glaucoma. Gentle and painless, SLT causes no damage to the eye – and takes just five minutes in your doctor’s office.
Vitreous Strands and Opacities (Floaters)
If you suffer from vitreous strands and opacities (commonly referred to as “eye floaters”), then you are already familiar with the frustrating visual disturbance caused by these cobweb and cloud-like shadows. A pain-free, non-invasive laser procedure, vitreolysis can provide much-needed relief from your eye floaters – and help you take back your quality of vision.
Age-Related Macular Degeneration (AMD)
A chronic eye disease, AMD is caused by damage to the eye’s macula and can result in vision loss in the central field of vision, including blurred central vision or a blind spot. Early detection is crucial. Detecting changes early through regular check-ups with your optometrist or ophthalmologist can help to slow the progression of AMD.
Diabetic Eye Disease
High blood sugar levels can damage blood vessels in the retina. This damage is referred to as Diabetic Retinopathy. If untreated over the long-term, Diabetic Retinopathy can cause visual impairment and blindness. In order to preserve vision and prevent progression of Diabetic Retionpathy, it is important to take control of your blood sugar levels, blood pressure, and blood cholesterol.
SLT. The Gentle Alternative for Glaucoma
SLT is a gentle laser therapy, which triggers a natural healing response in the eye to reduce the intraocular pressure associated with glaucoma. It effectively lowers eye pressure in the majority of patients, but the length of time that pressure remains low depends on many factors, including: age and type of glaucoma.
Don’t Let Eye Floaters Cloud Your Vision
Also known as floater laser treatment, vitreolysis is a non-invasive, pain-free procedure that can eliminate the visual disturbance caused by floaters. It is performed in your ophthalmologist’s office and typically takes 20-60 minutes per treatment session.
Over the years, Ellex has evolved from a small scientific laser company to a global leader in ophthalmic laser technology. Our steady expansion includes local sales and service support offices in North America, Japan, Europe and Australia and a network of distribution partners in more than 100 countries.
12 November 2013
Ellex today announced that it has recorded a solid improvement in group sales during the four months ended 31 October 2013 compared with the prior comparable period in the 2013 financial year. Of particular significance was a material improvement in sales in the USA. In July 2013 Ellex commenced sales of its world-leading SLT glaucoma laser range (Tango™ and Solo™) in the USA. Interest from ophthalmologists in the USA has been strong, with our US business recording key SLT sales at a number of sites. This, combined with the positive impact of additional new product introductions and the lowering of the Australian Dollar relative to the US Dollar, has resulted in a boost to US sales of approximately 80% compared to this time last year.
14 October 2013
Ellex Medical Lasers Limited (ASX:ELX), a pioneer in medical technologies for the diagnosis and treatment of eye disease, today announced that the results of a pilot study to investigate the efficacy of the Company’s proprietary Retinal Rejuvenation Therapy (2RT) in the treatment of early Age-Related Macular Degeneration (AMD) have been released and published in the peer-reviewed, scientific publication Clinical & Experimental Ophthalmology.
26 September 2013
Ellex Medical Lasers Limited (ASX:ELX), a pioneer in medical technologies for the diagnosis and treatment of eye disease, today announced that its portfolio of industry-leading SLT glaucoma lasers has been qualified for inclusion on its US Government Services Administration (GSA) contract. Effective 1 October 2013, the Company’s SLT lasers can be sold to US government medical facilities in the USA and around the world.
View Share Price
Note: Prices are delayed by at least 20 minutes and are sourced from the Australian Stock Exchange.
Retrieving price information indicates your acceptance of the conditions.